Key result
Hyperglycemia in pregnancy raises congenital heart disease risk by disrupting cardiac neural crest cell development.
Why the study?
Hyperglycemia in pregnancy is an important independent risk factor for congenital heart disease in offspring, with an increasing number of women of childbearing age experiencing gestational hyperglycemia.
Does hyperglycemia in pregnancy increase the risk of congenital heart disease in offspring?
Does hyperglycemia in pregnancy increase the risk of congenital heart disease in offspring?
This review highlights the molecular mechanisms, including oxidative stress and signaling pathway dysregulation, by which maternal hyperglycemia induces congenital heart disease, emphasizing the need for early glycemic control.
Maternal hyperglycemia may raise congenital heart disease risk; leaves open prospective trials on glycemic control and mechanism-targeted prevention.
Hyperglycemia in pregnancy (HIP) is an important independent risk factor for congenital heart disease (CHD) in offspring. With an increasing number of women of childbearing age experiencing gestational hyperglycemia, the impact of an intrauterine hyperglycemic environment on fetal development has drawn significant attention. However, the teratogenic mechanisms underlying its effects on cardiac development remain incompletely understood. This review systematically analyzes relevant literature to summarize its underlying mechanisms and key findings: A hyperglycemic environment disrupts cardiac neural crest cell migration, differentiation, and the proliferation/apoptosis balance of cardiomyocytes by inducing oxidative stress, endoplasmic reticulum stress, and inflammatory responses during critical embryonic developmental stages (cardiac ridge and heart tube formation). The core molecular mechanisms involve abnormalities in signaling pathways such as Wnt, TGFβ, and Notch, as well as dysregulation of epigenetic controls including histone modifications and DNA methylation. Concurrently, in-depth research into the molecular mechanisms by which HIP contributes to CHD provides direction for developing early warning biomarkers (such as specific miRNAs and epigenetic markers) and potential therapeutic targets. It also offers insights into advancing intervention from pregnancy to the preconception stage and enabling proactive, lifecycle management of maternal and fetal risks through multidisciplinary collaboration. Keywords Hyperglycemia in pregnancy; congenital heart disease; maternal hyperglycemia; pregestational diabetes mellitus; gestational diabetes mellitus; maternal diabetes; cardiac development; cardiovascular disease Cite This Article APA Style He, J., Alifu, A., Wang, H., Chen, R. (2026). Research Advances on the Mechanisms and Clinical Outcomes of Hyperglycemia in Pregnancy Leading to Congenital Heart Disease in Offspring. Structural and Congenital Heart Disease , 21 (1) , 7. https://doi.org/10.32604/schd.2026.075858 Vancouver Style He J, Alifu A, Wang H, Chen R. Research Advances on the Mechanisms and Clinical Outcomes of Hyperglycemia in Pregnancy Leading to Congenital Heart Disease in Offspring. Structural Congenital Heart Disease. 2026;21(1):7. https://doi.org/10.32604/schd.2026.075858 IEEE Style J. He, A. Alifu, H. Wang, and R. Chen, “Research Advances on the Mechanisms and Clinical Outcomes of Hyperglycemia in Pregnancy Leading to Congenital Heart Disease in Offspring,” Structural Congenital Heart Disease , vol. 21, no. 1, pp. 7, 2026. https://doi.org/10.32604/schd.2026.075858 BibTex EndNote RIS
No takes yet. Share an insight, caveat, or question.
He et al. (2026) conducted a review in Hyperglycemia in pregnancy and congenital heart disease. Hyperglycemia in pregnancy was evaluated. Hyperglycemia in pregnancy disrupts cardiac neural crest cell migration and differentiation through oxidative stress and epigenetic dysregulation, increasing the risk of congenital heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: